Relationship between talimogene laherparepvec and intratumoral CD8+density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study

被引：0

|

作者：

Malvehy, J. ^{[1
,2
]}

Samoylenko, I. ^{[3
]}

Schadendorf, D. ^{[4
]}

Gutzmer, R. ^{[5
]}

Grob, J. -J. ^{[6
,7
]}

Sacco, J. ^{[8
]}

Gorski, K. S. ^{[9
]}

Pickett, C. A. ^{[9
]}

Liu, K. ^{[9
]}

Gogas, H. ^{[10
]}

机构：

[1] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain

[2] Hosp Clin Barcelona, iDIBAPS, Barcelona, Spain

[3] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[4] Univ Duisburg Essen, Dept Dermatol, Essen, Germany

[5] Hannover Med Sch, Skin Canc Ctr Hannover, Hannover, Germany

[6] Aix Marseille Univ, Marseille, France

[7] APHM Timone, Marseille, France

[8] Clatterbridge Canc Ctr, Liverpool, Merseyside, England

[9] Amgen Inc, Thousand Oaks, CA 91320 USA

[10] Univ Athens, Sch Med, Laiko Gen Hosp, Dept Med 1, Athens, Greece

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2017年 / 31卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

FC2.6

引用

收藏

页码：39 / 40

页数：2

相关论文

共 23 条

[21] Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma
Sacco, Joseph J.
Harrington, Kevin Joseph
Olsson-Brown, Anna
Chan, Tze Y.
Nenclares, Pablo
Leslie, Isla
Bommareddy, Praveen
Kalbasi, Alireza
Xie, Ben
Mishal, Moran
Cohan, David Michael
Skolariki, Aglaia
Middleton, Mark R.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22] Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors
Diab, Adi
Tannir, Nizar
Cho, Daniel
Papadimitrakopoulou, Vali
Bernatchez, Chantale
Haymaker, Cara
Bentebibel, Salah Eddine
Curti, Brendan
Wong, Michael
Tykodi, Scott
Puzanoff, Igor
Smalberg, Ira
Gergel, Ivan
Tagliaferri, Mary
Zalevsky, Jonathan
Hoch, Ute
Aung, Sandra
Imperiale, Michael
Clemens, Wendy
Kluger, Harriet
Hurwitz, Michael
Hwu, Patrick
Sznol, Mario
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[23] Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study
Gane, Edward J.
Kocinsky, Hetal
Schwabe, Christian
Mader, Michael
Suri, Vithika
Donohue, Mary K.
Huang, Mingjun
Hui, James
Yang, Joanna
Apelian, David
HEPATOLOGY, 2014, 60 (06) : 1281A - 1282A